Internet Archive Scholar

Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients

Larry L. Luchsinger, Brett Ransegnola, Daniel Jin, Frauke Muecksch, Yiska Weisblum, Weili Bao, Parakkal Jovvian George, Marilis Rodriguez, Nancy Tricoche, Fabian Schmidt, Chengjie Gao, Shabnam Jawahar (+8 others)
2020 Journal of Clinical Microbiology  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (2.6 MB)
https://web.archive.org/web/20210121055034/https://jcm.asm.org/content/jcm/58/12/e02005-20.full.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL. The file type is application/pdf.

The development of neutralizing antibodies (nAb) against SARS-CoV-2, following infection or vaccination, is likely to be critical for the development of sufficient population immunity to drive cessation of the COVID19 pandemic. A large number of serologic tests, platforms and methodologies are being employed to determine seroprevalence in populations to select convalescent plasmas for therapeutic trials, and to guide policies about reopening. However, tests have substantial variability in
more » ... ivity and specificity, and their ability to quantitatively predict levels of nAb is unknown. We collected 370 unique donors enrolled in the New York Blood Center Convalescent Plasma Program between April and May of 2020. We measured levels of antibodies in convalescent plasma using commercially available SARS-CoV-2 detection tests and in-house ELISA assays and correlated serological measurements with nAb activity measured using pseudotyped virus particles, which offer the most informative assessment of antiviral activity of patient sera against viral infection. Our data show that a large proportion of convalescent plasma samples have modest antibody levels and that commercially available tests have varying degrees of accuracy in predicting nAb activity. We found the Ortho Anti-SARS-CoV-2 Total Ig and IgG high throughput serological assays (HTSAs), as well as the Abbott SARS-CoV-2 IgG assay, quantify levels of antibodies that strongly correlate with nAb assays and are consistent with gold-standard ELISA assay results. These findings provide immediate clinical relevance to serology results that can be equated to nAb activity and could serve as a valuable 'roadmap' to guide the choice and interpretation of serological tests for SARS-CoV-2.
doi:10.1128/jcm.02005-20 pmid:32917729 fatcat:owhbwhnutjhy3eadso2ei4bzne
Citation

Larry L. Luchsinger, Brett Ransegnola, Daniel Jin, Frauke Muecksch, Yiska Weisblum, Weili Bao, Parakkal Jovvian George, Marilis Rodriguez, Nancy Tricoche, Fabian Schmidt, Chengjie Gao, Shabnam Jawahar, Mouli Pal, Emily Schnall, Huan Zhang, Donna Strauss, Karina Yazdanbakhsh, Christopher D. Hillyer, Paul D. Bieniasz, Theodora Hatziioannou. "Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients." Journal of Clinical Microbiology 58.12 (2020)